 Genprex, Inc. NASDAQ:GNPX told investors it has entered into an exclusive license agreement with the University of Pittsburgh, granting the company a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how. The Austin, Texas-based company said the agreements are all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. 